Approval · Notice of Compliance 30970 · 2023

XCOPRI: Notice of Compliance 30970

Issued June 12, 2023

A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.

Notice number: 30970
Date: June 12, 2023
Company: Endo Ventures Ltd
Product type: Prescription Pharmaceutical
Submission: New Drug Submission (NDS)
Submission class: New Active Substance (NAS)

Products in this notice

Brand	DIN	Status today
XCOPRI	02538652	Marketed
XCOPRI	02538660	Marketed
XCOPRI	02538725	Marketed
XCOPRI	02538733	Marketed
XCOPRI	02538741	Marketed
XCOPRI	02538768	Marketed
XCOPRI	02538806	Approved
XCOPRI	02538792	Approved
XCOPRI	02538784	Marketed
XCOPRI	02538776	Marketed
XCOPRI	02538814	Approved

Medicinal ingredients

CENOBAMATE 12.5 MG per TAB
CENOBAMATE 25 MG per TAB
CENOBAMATE 50 MG per TAB
CENOBAMATE 100 MG per TAB
CENOBAMATE 150 MG per TAB
CENOBAMATE 200 MG per TAB
CENOBAMATE 100 MG per NIL
CENOBAMATE 150 MG per NIL
CENOBAMATE 200 MG per NIL
CENOBAMATE 50 MG per NIL
CENOBAMATE 12.5 MG per NIL
CENOBAMATE 25 MG per NIL